Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28302050 | 1.00 | ACACB (0.52) | ACACBGRIA4DHFRTSHRSMN1; SMN2 | |
| SCHEMBL28303465 | 1.00 | ACACB (0.52) | ACACBGRIA4DHFRTSHRSMN1; SMN2 | |
| SCHEMBL9510562 | 0.84 | ACACB (0.54) | ACACBTSHRSMN1; SMN2TDP1NPC1 | |
| SCHEMBL11322693 | 0.82 | ACACB (0.52) | ACACBGRIA4SMN1; SMN2NPC1MTNR1A | |
| SCHEMBL4760955 | 0.82 | ACACB (0.52) | ACACBTSHRNPC1MTNR1AMTNR1B | |
| SCHEMBL2091303 | 0.81 | MTNR1A (0.60) | ACACBSMN1; SMN2TDP1NPC1MTNR1A | |
| SCHEMBL8384245 | 0.81 | MTNR1A (0.60) | ACACBSMN1; SMN2TDP1NPC1MTNR1A | |
| SCHEMBL8384291 | 0.81 | MTNR1A (0.60) | ACACBSMN1; SMN2TDP1NPC1MTNR1A | |
| SCHEMBL9512709 | 0.79 | MTNR1A (0.67) | ACACBSMN1; SMN2NPC1MTNR1AMTNR1B | |
| SCHEMBL9212485 | 0.79 | NPC1 (0.41) | ACACBGRIA4DHFRTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109942499-B | Quinazoline derivative and preparation method and application thereof | 湖南中医药大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-109942499-A | Quinazoline derivant and its preparation method and application | 湖南中医药大学 | 2019-06-28 | — | — | CN | disclosed |
| EP-1996567-B1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8207350-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBOTT LABORATORIES (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2134676-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | Addex Pharma SA (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20090048298-A1 | Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome | ABBOTT LABORATORIES (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| US-20070219258-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219258-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | ACACB 2/4885GRIA4 3874/4885DHFR 1648/4885 |
| US-20090048298-A1 | Novel acetyl-CoA Carboxylase (ACC) Inhibitors and their use in Diabetes, Obesity and Metabolic Syndrome | ACACA, ACACB, ACAT1 | ACACB 2/4885GRIA4 3874/4885DHFR 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.